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Abstract
Background: Leptin can have a direct effect on endothelial and vascular smooth muscle cells and high level of
leptin is involved in the pathogenesis of atherosclerosis. This study aimed to determine the relationship between
leptin/adiponectin (L/A) ratio and the extent and severity of coronary artery disease (CAD).
Methods: This case-control study was conducted in an educational hospital in Ilam, Iran from June 2014 to
September 2015. Totally 300 participants including 150 patients with CAD (case group) and 150 healthy individuals
(control group) were selected and their plasma leptin, adiponectin and leptin/adiponectin ratio was measured. The
extent and severity of coronary artery disease were assayed based on the number of involved vessels and Gensini
score (GS) and the relation between scores and L/A findings were compared between cases and controls.
Results: Totally, 300 participants including 150 (42.7% male), mean age 59.5 ± 11.4 years as cases and 150 (50.7% male),
mean age 59.8 ± 10.7 as controls were analyzed. Plasma level of leptin and L/A ratio were higher in cases compared to
controls, but level of adiponectin was significantly lower in CAD patients than the control group. More number of
involved coronary vessels was significantly correlated to higher level of plasma leptin, L/A ratio and lower level of
adiponectin among case group. Moreover, adiponectin was negatively and leptin or L/A ratio were positively
correlated with number of involved vessels. 7.3% of cases had only one involved vessel, 42.7% had two involved
vessels, and 50% of total patients had involved vessels and the mean ± SD of GS in the case group was 23.6 ± 6.9.
Conclusions: Plasma levels of leptin, and adiponectin can indicate the extent of coronary artery diseases but leptin
may be a better marker of extent of CAD than either L/A ratio or adiponectin separately.
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Background
Coronary artery disease is one of the most common
causes of mortality and morbidity worldwide [1]. Despite
the high prevalence of this disease, the exact mecha-
nisms associated with the development of atherosclerosis
remain unclear [2]. Several risk factors associated with
the progression of coronary artery disease including
obesity, smoking, hypertension, hyperlipidemia and
other chronic inflammatory conditions have been identi-
fied [3]. Studies suggest that obesity is the one of the
most important risk factors for CAD and one of the im-
portant factors underlying the link between obesity and
CAD is the leptin and adiponectin levels secreted by adi-
pose tissue [4]. Although the main role of leptin is hu-
man energy homeostasis and body weight regulation by
the brain [5], it also has a variety of functions, such as
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participation in inflammatory processes, immune func-
tion [6], angiogenesis and vascular functions [7]. In
addition, leptin can have a direct effect on endothelial
and vascular smooth muscle cells [8] and a high level of
leptin is involved in the pathogenesis of atherosclerosis
[9]. Some reports have shown a significant independent
association between leptin and coronary artery calcifica-
tion (CAC) [10] and the intima-media thickness of
common carotid artery in patients with type 2 diabetes
mellitus [11]. Though some studies have shown that lep-
tin is an independent risk factor for CHD [12]; however,
studies on leptin and CAD have also reported conflicting
results [13]. Adiponectin is known as a cardioprotective
and anti-atherogenic mediator [14] and its plasma levels
are reduced in obese and dyslipidemic individuals [15].
Some studies have reported correlations between hypoa-
diponectinemia and an increased risk of CAD [16].
Despite extensive studies, the pro-atherogenic effects of
leptin and the anti-atherogenic effects of adiponectin in
atherosclerotic patients have not been fully defined. The
plasma L/A ratio may be a more appropriate indicator
for predicting the risk of CAD compared to leptin or
adiponectin serum level alone [17, 18]. However, the re-
lationship between L/A ratio and the extent and severity
of coronary artery disease is not clear. The aim of this
study was to investigate the relationship between the
leptin and L/A ratio indices and the severity and extent
of coronary artery disease using angiography and GS.
Methods
Study design
This case-control study was conducted in patients re-
ferred to Mustafa Khomeini Hospital, an educational
hospital and major referral medical center, in Ilam, Iran
between June 2014 and September 2015. During the
mentioned period, all patients with inclusion criteria
were selected as cases and for each case a healthy indi-
vidual at the same date was randomly selected as con-
trol. A total of 150 CAD patients underwent coronary
angiography in Cardiology Department (case group) and
150 healthy individuals from the same center (control
group) were selected as the study subjects. Controls did
not show any coronary involvements based on angio-
graphic results. Inclusion criteria for participants were as
follow: typical chest pain, coronary involvement after
non-invasive evaluations such as physical exam or scan,
and post-myocardial infarction (MI), and exclusion cri-
teria were as follow: heart failure (left ventricular
ejection fraction < 40%), history of acute myocardial in-
farction, history of coronary artery diseases by coronary
angioplasty, acute or chronic renal failure, hepatic dis-
eases such as nonalcoholic fatty liver disease (NAFLD)
or cirrhosis, chronic infection, malignancy, any auto-
immune diseases or hematological disorders and any
inflammatory or metabolic diseases. To eliminate the ef-
fect of glucose and lipid metabolism, patients with
diabetes were excluded from the study. Using a stan-
dardized questionnaire, the demographic characteristics
of participants, including age, sex, cardiovascular risk
factors such as smoking, family history of heart diseases,
and hypertension (HTN), were obtained. A complete
physical examination was performed, and blood pressure
(BP) was taken from each patient’s right arm, after 10
min resting in a quiet room, in a seating position. Two
successive BP readings were obtained, at 5 min intervals,
and their average was considered as patient’s blood pres-
sure. Hypertension was defined as systolic blood pres-
sure (SBP) ≥ 140 mmHg or a diastolic blood pressure
(DBP) ≥ 90 mmHg or the use of antihypertensive drugs
[19]. The weight and height of participants were mea-
sured using a digital scale and tapeline by the same indi-
vidual. Body mass index (BMI, kg /m2) was calculated as
the weight (kg) divided by height (m2). Waist circumfer-
ence (WC) was measured at the end of expiration at the
narrowest point of the abdomen, approximately 5.2 cm
between the umbilicus and hip. This measurement was
performed at the maximum bulge point in a standing
position, with closed feet.
Coronary angiography
Coronary angiography was carried out using the stand-
ard Judkins technique and a semi-quantitative coronary
angiographic system [20]. The angiographic results were
collected by two cardiologists, and based on the different
findings, the patients were divided into 3 categories. The
first category was determined according to the number
of involved vessels indicating 1, 2, or 3 involved vessels
groups; the second category was determined according
to the type of involved vessels indicating the place of in-
volved vessels such as left anterior descending artery
(LAD), right coronary artery (RCA), left circumflex ar-
tery (LCX), and the diagonal or marginal artery; and the
third category was determined according to the rate of
stenosis of the vessels indicating a percentage of stenosis
such as less than 50%, 50–75% and more than 75%. In
this study, coronary artery stenosis was assayed using
Gensini scores, which represents both the severity and
the extent of coronary atherosclerosis [21]. Gensini score
is a widely used mean of quantifying angiographic
atherosclerosis, where a zero score indicates absence of
atherosclerotic disease. The Gensini score accounts for
the degree of artery narrowing as well as locations of
narrowing. The severity of stenosis is indicated by the
reduction in lumen diameter, and a nonlinear score is
assigned to each lesion based upon it.
The studied patients were divided into the following
six groups according to the American Heart Association
protocols: Score 1—stenosis < 25%; Score 2—stenosis
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26–50%; Score 4—stenosis 51–75%; Score 8—stenosis
76–90%; Score 16—stenosis 91–99%; and Score 32—
stenosis 100%.
Another grouping of patients was based on the severity
of coronary artery lesions using GS as normal coronary
artery (Score 0–1), mild lesions (Score 2–20), moderate
lesions (Score 20–40), and severe lesions (Score > 40).
Biochemical assay
After a 12-h fasting, 10 ml/l of vein blood sample was
obtained from each patient and after centrifuging by
1000 g for 10 min, and the samples were stored at −
70 °C. Lipid profiles, including triglycerides (TGs), chol-
esterol (Chol), low density lipoprotein cholesterol (LDL-
C) and high density lipoprotein cholesterol (HDL-C),
and plasma glucose were measured using routine labora-
tory techniques (Pars Azmoon kit, Catalog No 1500017,
Tehran, Iran for TG and Chol and Zist Shimi kit, Serial
No D00749, Tehran, Iran for HDL-C respectively). LDL-
C was estimated based on direct measurement with
autoanalyzer. ELISA kits were used to assay the ratios of
serum adiponectin (R&D Systems, USA) and serum lep-
tin (D&G Diagnostics, Germany), and the assays were
conducted according to the manufacturer’s protocol.
Statistical analysis
Data were expressed as the mean ± SD for quantitative
variables and/or frequencies for qualitative variables.
The normality of data was assessed using the
Kolmogorov-Smirnov test. Student’s t-test and the chi-
square tests were applied appropriately. Pearson correl-
ation coefficient method was applied for the correlation
between plasma leptin, adiponectin or the L/A ratios
and the demographic or clinical characteristics of partic-
ipants. In addition, Spearman correlation coefficient
method was applied for variables without normal distri-
bution. Logistic regression and multivariate analysis were
applied for testing the predicting value of some plasma
factors for CAD extension and severity. P value equal or
less than 0.05 was considered statistically significant for
all variables. The data analysis was performed via IBM
SPSS Statistics for Windows, version 2019 (IBM Corp.,
Armonk, N.Y., USA). The Epanechnikov Kernel Smooth-
ing was applied to show a non- linear association be-
tween adiponectin or leptin and Gensini score.
Results
All demographic, laboratory, anthropometric and angio-
graphic findings of participants are indicated in Table 1.
The male percentage and mean ± SD for age among con-
trol and case groups were 50.7%; 59.8 ± 10.7 and 42.7%;
59.5 ± 11.4 years respectively and there were no signifi-
cant differences for gender or age between groups (p =
0.101 and p = 0.802, respectively). The angiographic
evaluations of patients showed that 7.3% of cases had
only one involved vessel, 42.7% had two involved vessels,
and 50% of total patients had involved vessels and the
mean ± SD of Gensini score in the case group was
23.6 ± 6.9.
Logistic regression and multivariate analysis were ap-
plied for testing the predicting value of some plasma fac-
tors for CAD extension and severity. Since the difference
between mean plasma leptin among cases and controls
was high (85.87 ± 10.69 vs. 9.84 ± 5.36) with a significant
difference (p = 0.0001), at the first step, the logistic iden-
tified only this factor as a powerful variable and other
factors could not enter the equation. After deleting this
variable three other factors were identified significantly
(adiponectin, L/A ratio and waist circumference). There-
fore, four most associated predictors for CAD extension
were as follows: leptin, adiponectin, L/A ratio and waist
circumference and the best predictor value for CAD ex-
tension in the current study was LEPTIN (Table 2).
The mean ± SD for the serum leptin level, based on
the number of involved coronary vessels, is shown by
Fig. 1. Based on the findings of this study, the mean
serum leptin level in patients with one, two and three in-
volved coronary vessels were 27.34 ± 10.32 ng/ml,
47.46 ± 15.43 ng/ml and 54.35 ± 15.43 ng/ml respectively
and a positive and significant correlation between serum
leptin levels and the number of coronary involved ves-
sels was revealed (p = 0.008).
Also, logistic regression and t-test was applied for
CAD extension and the results showed that those with 2
and 3 vessels involvement have 3.6 and 5.6 times higher
chance of CAD than those with one vessel involvement
respectively.
The mean ± SD for the serum adiponectin level, based
on the number of coronary involved vessels, is shown by
Fig. 2. The mean ± SD serum adiponectin levels for one,
two and three involved vessels were 24.24 ± 4.53 IU/ml,
20.78 ± 6.52 IU/ml, and 18.60 ± 7.54 IU/ml respectively
and the correlation between the serum adiponectin
levels and the number of involved coronary vessels was
significant (p = 0.000).
The mean and standard deviation of L/A ratio, based
on the number of involved coronary vessels is shown by
Fig. 3. The mean serum L/A ratio among one, two and
three involved coronary vessels were 1.84 ± 0.54, 3.90 ±
1.12 and 4.13 ± 0.98 respectively. There was also a sig-
nificant correlation between the serum L/A ratio and the
number of involved vessels (p = 0.001).
The relationship between serum levels of adiponectin
and the GS is shown by Fig. 4. According to the findings
of this study, as the levels of adiponectin was increased,
the GS was decreased, indicating an inverse association
between serum adiponectin levels and the GS but this
relationship was not significant.
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The relationship between serum leptin levels and the
GS is shown by Fig. 5 and based on the findings, the GS
increased with increasing the serum levels of leptin, indi-
cating a direct relationship between the serum leptin
levels and GS insignificantly.
Comparison between the serum L/A ratio and the GS
also revealed an insignificant positive association and as
the serum L/A ratio increased, the GS increased too
(Fig. 6).
Discussion
The current study investigated any relationship between
the leptin, adiponectin and L/A ratio and the extent or
severity of coronary artery disease based on the number
of involved vessels and GS, and this was the first study
in this field. In fact, several studies have reported the as-
sociation between leptin or adiponectin and CAD separ-
ately; however, there is no study to show any correlation
between the L/A ratio and angiographic findings. Our
study findings showed that the serum adiponectin level
among case group was significantly lower than that
among healthy individuals. Additionally, a significant
and inverse relationship between serum adiponectin
levels and the extent of CAD, according to number of
involved vessels, was revealed among patients. According
to this finding, hypoadiponectinemia was identified as an
independent risk factor for the extent of CAD and this
finding was in accordance with previous reports [22].
Some studies have shown that hypoadiponectinemia was
associated with CAD, particularly in the content of obes-
ity, hyperinsulinemia, diabetes type 2, and dyslipidemia
[23, 24]. Another study reported that hypoadiponectine-
mia could increase the risk of atherosclerosis and acute
coronary syndrome [25]. Different mechanisms exist re-
garding the protective role of adiponectin in the control
of atherosclerosis, but its anti-atherogenic role is not
Table 1 Demographic and clinical characteristics of study participants
Variables Control group
n = 150
Case group
n = 150
P value
Demographic data
Sex, Male, n (%) 76 (50.66) 64 (42.66) 0.101
Age (years) 59.78 ± 10.65 59.46 ± 11.42 0.802
Smoking, n (%) 45 (30) 58 (38.66) 0.058
Hypertension, n (%) 97 (64.66) 96 (64) 0.500
Familial history, n (%) 43 (28.66) 40 (26.66) 0.398
Anthropometric data
Height (cm), mean ± SD 169.63 ± 22.01 171.43 ± 19.38 0.001
Weight (kg), mean ± SD 76.75 ± 25.27 91.26 ± 41.34 0.001
BMI (kg/m2), mean ± SD 25.78 ± 5.97 28.78 ± 8.15 0.001
WC (cm), mean ± SD 99.17 ± 5.89 101.33 ± 5.19 0.803
Laboratory data
TG (mg/dl), mean ± SD 128.01 ± 77.164 134.34 ± 25.43 0.480
Chol (mg/dl), mean ± SD 124.80 ± 59.66 128.91 ± 46.54 0.551
LDL (mg/dl), mean ± SD 97.82 ± 25.65 104.86 ± 31.69 0.324
HDL (mg/dl), mean ± SD 54.55 ± 10.90 46.43 ± 11.21 0.453
FBS (mg/dl), mean ± SD 110.34 ± 5.34 119.34 ± 6.43 0.860
Leptin (ng/ml), (median (range)) 9.83 (7.99–11.76) 85.87 (82.20–88.37) 0.001
Adiponectin (IU/ml), (median (range)) 28.68 (26.42–30.05) 8.65 (6.78–10.65) 0.001
Leptin/adiponectin ratio, (median (range)) 0.51 (0.35–0.71) 7.45 (6.12–7.77) 0.001
Angiographic data
Vessel involvement, n (%) –
1 VD – 11 (7.33)
2 VD – 64 (42.66)
3 VD – 75 (50)
Gensini score (mean ± SD) – 23.62 ± 6.89
BMI Body Mass Index, WC Waist Circumference, TG Triglyceride, Chol Cholesterol, LDL Low Density Lipoprotein, HDL High Density Lipoprotein, FBS Fasting Blood
Sugar, VD Vessel Diseased
Rahmani et al. BMC Cardiovascular Disorders          (2020) 20:474 Page 4 of 9
clear [25]; nevertheless, some studies reported that the
anti-atherogenic effect of adiponectin was mediated
through the inhibition of neointimal formation [26]. In
vitro studies have shown a progressive neointimal dam-
age and proliferation of smooth muscle in damaged ar-
teries among mice without adiponectin [27, 28].
Furthermore, some studies have shown that the accumu-
lation of adiponectin in the sub-endothelial spaces of
damaged arteries causes an inhibition of genes related to
inflammation, such as tumor necrosis factor-α (TNF-α),
and markers related to endothelial malfunction, such as
VCAM-1 and ICAM-1. With these effects, adiponectin
may inhibit the adhesion of monocytes to the endothelial
of cells, which is the first step in arteriogenesis, and their
migration to the sub-endothelial spaces, as well as im-
pose anti-atherogenic effects. The adiponectin-based in-
hibition of lipid accumulation in macrophages and
increasing blood flow, resulted from vasodilator effects
through nitric oxide (NO) production, are other benefi-
cial effects of adiponectin in the inhibition of athero-
sclerosis [29, 30]. Our study showed that adiponectin
has an inverse but insignificant relationship with the GS,
namely an increase in the GS was associated to a reduc-
tion of adiponectin level among CAD patients. A study
by Fukuta et al. reported that lower level of adiponectin
was associated with LV diastolic dysfunction, among pa-
tients with CAD [31]. Another study reported that leptin
was associated with increased atherogenic processes
[32]. The results of our study indicated that serum levels
of leptin were significantly higher among CAD patients
than in healthy control subjects and leptin was also dir-
ectly related to the extent of coronary artery disease,
based on number of involved vessels. Unlike adiponec-
tin, leptin significantly increased with increasing the
numbers of involved vessels in CAD patients. Previous
Fig. 1 Mean ± SD of serum leptin level, based on the number of
involved vessels (VD) in participants
Table 2 Bivariate relationship between different variables and serum leptin, adiponectin and L/A ratio in participants
Variable Leptin (ng/ml) Adiponectin (IU/ml) Leptin/adiponectin
r P r p r p
Age (years −.04 .45 −.06 .32 .010 .86
Hypertension, n (%) . 04 .49 .02 .69 −.004 .95
FBS (mg/dl) .01 .86 −.05 .43 .04 .51
TG (mg/dl) −.02 .72 .01 .91 .02 .79
Chol (mg/dl) .02 .77 −.04 .49 .02 .78
LDL (mg/dl) −.02 .71 −.04 .45 .02 .68
HDL (mg/dl) .01 .83 −.05 .37 .06 .31
Height (cm) −.09 .09 .16** .007 −.10 .08
Weight (kg) .04 .51 −.13* .02 .06 .27
BMI (kg/m2) .06 .33 −.13* .02 .07 .26
WC (cm) −.01 .83 −.09 .10 .04 .47
Vessel involvement, n (%) .15** .008 −.22** .000 .18** .001
Stenosis (%) .08 .16 −.06 .30 .06 .30
Gensini score (mean ± SD) −.01 .86 −.06 .33 .03 .64
BMI Body Mass Index, WC Waist Circumference, TG Triglyceride, Chol Cholesterol, LDL Low Density Lipoprotein, HDL High Density Lipoprotein, FBS Fasting Blood
Sugar, VD Vessel Diseased
Fig. 2 Mean ± SD of serum adiponectin level, based on the number
of involved vessels (VD) in participants
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studies have shown a harmful effect of leptin in the
pathogenesis of atherosclerosis and demonstrated that
leptin was an independent risk factor for CAD [33]. It
has been shown that leptin can increase the risk of CAD
more than other risk factors for cardiovascular diseases
such as sex, race, smoking, and body mass index [34]. A
study reported that after excluding other risk factors, the
odds ratio for increased disease severity among patients
with high leptin levels was preserved [31]. The athero-
genic mechanisms of leptin have not been clearly identi-
fied but its beneficial effects, such as increasing NO
production, improving coronary blood flow [35] and its
role in the process of angiogenesis have been reported
[36]. On the other hand, some adverse effects of leptin
have such as direct contact with the components of
metabolic syndrome and impaired fibrinolysis have been
reported [37]. Based on different reports, leptin can have
other effects, such as obesity-related hypertension as
well as pro-thrombotic properties, in the cardiovascular
system [38–40]. Though the current study showed an
higher significant serum level of Leptin among CAD pa-
tients than the healthy individuals, but it’s correlation
with GS and CAD severity was not significant. The dif-
ference between our findings about relationship between
leptin and severity of CAD with other reports is not
clear but it may bay associated with the performance of
coronary angiography and its interpretation by interven-
tional cardiologists and score estimation or even a lower
number of evaluated patients in the current study.
Based on the possible atherogenic, thrombotic and an-
giogenic effects of leptin, and existence of its receptors
in the endothelial cells, rising of this factor in the blood
may predict restenosis after some vascular accidents
[41–43]. There is a controversy in the effects of leptin
on CAD patients and though several study have reported
a modest relationship between higher level of plasma
leptin and risk of CAD incident [13] other have shown a
protective effect for leptin [44, 45].
An important result of the current study was a signifi-
cantly higher L/A ratio in patients with CAD in
Fig. 4 Correlations between serum adiponectin levels and Ginsini score in participants
Fig. 3 Mean ± SD of leptin/adiponectin ratio, based on the number
of involved vessels (VD) in partcipants
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comparison with healthy individuals. This study also re-
vealed that the L/A ratio was directly correlated with the
extent but not severity of coronary artery disease. Add-
itionally, the L/A ratio showed a direct correlation with
the number of involved coronary vessels, indicating that
patients with three-vessel coronary artery involvement
had a higher serum L/A ratio than patients with two or
one coronary artery involvement. A few studies have in-
vestigated the effects of serum L/A ratio on CAD. Kap-
pelle and colleagues showed that the serum L/A ratio
Fig. 6 Correlations between leptin/adiponectin ratio and Gensini score in participants
Fig. 5 Correlations between serum leptin levels and Ginsini score in participants
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could be a useful marker for predicting the risk of the
first cardiovascular event in men [46]. The advantage of
our study was the investigation of serum L/A ratio in
CAD patients compared with healthy subjects and its as-
sociation with the numbers of involved coronary arteries
and GS. Though the predictor effects of either serum
leptin or adiponectin for the severity and extent of cor-
onary artery disease has been reported previously [13],
and our findings were almost in consistence with these
reports; however, the current study revealed that the
serum L/A ratio was another predictor rather than either
leptin or adiponectin for CAD separately. This study was
limited to compare the factors related to endothelial dys-
function or cardiac anatomic findings with the serum
leptin, or adiponectin levels and/or the serum L/A ratio.
A future cohort study, examining the relationship be-
tween the serum L/A ratio and patient’s prognosis would
be helpful.
In the current study, serum levels of leptin were asso-
ciated with incident of CAD and it was also directly re-
lated to the extent of coronary artery disease. As the
number of involved vessels was higher, the serum level
of leptin was higher too and this association could be
shown as an increasing trend, so that leptin values in pa-
tients with one involved vessel compared to controls and
those with two involved vessels compared to one and
those with three involved vessels compared to two in-
volved vessels were higher. A similar trend was revealed
for the L/A ratio and the number of involved vessels in
CAD patients but with an insignificant difference be-
tween 3 vessels compared to two vessels; however, in
case of serum level of adiponectin, a negative relation-
ship with involved vessels was appeared. Based on these
results two concepts could be considered. Firstly, the
serum level of both leption and L/A ratio are related to
the increase in coronary atherosclerotic load. Secondly,
at the start and during the progression of coronary ath-
erosclerosis, the release of proaterogenic adipocytokines
is increased, may be due to increased inflammatory
process, and after a primary inflammation, this
phenomenon declines and the serum level of leptin does
not increase as markedly.
Conclusion
As a conclusion, the effects of serum level of leptin or
adiponectin were higher among CAD patients than
healthy individuals and associated with the extent of cor-
onary artery disease and our findings were in consistence
with other previously reports. Also, the current study re-
vealed that the serum level of leptin was a better pre-
dictor than either L/A ratio or adiponectin separately.
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